Completeness of data on malignant melanoma skin sites and morphology in Croatian National Cancer Registry 2000-2014: an overview of recent progress

Mortality rates and five-year relative survival for malignant melanomaMM of the skin in Croatia are poor compared with most Europeancountries. Epidemiological data recorded at the National Cancer Registry(CNCR) are used for informing various decision-makers and researchers, aswell as comparisons with other countries. We analyzed CNCR data on MMskin sites and morphology for 2000-2007 and 2008-2014 and comparedthem with European 2000-2007 data. We further stratified skin site analysesin Croatia by sex, different age groups, and sources of reports. We found 52%of case with “non-specified sites” in Croatia in 2000-2007; however, that ratiodecreased to 36% in 2008-2014, with 29% of registered MM cases occurringon the trunk, 22% on the limbs, and 13% on the head and neck. The ratio of“non-specified sites” cases in reports originating from university hospitalsdecreased by 25% and by 9.2% in those from general hospitals. The ratioof “not otherwise specified” among histologically verified cases decreasedfrom 96% in 2000-2007 to 84% in 2008-2014. Our results reveal a substantialratio of inadequately reported cases, in particular when compared to data atthe European level, where in 2000-2007 only 7.7% of cases were from “nonspecifiedsites” and 19% were of non-specified morphology. Irrespective ofrecent progress, the proportion of unspecified cases still hampers insight into sitedistribution by subgroups. A further increase in the overall completeness ofMM data within CNCR is needed to enable research-informed improvementof melanoma control in the country. Our findings call for engagement ofall stakeholders in optimization of the national melanoma registration processesand using models such as RegisTree to facilitate these initiatives.</p

Completeness of data on malignant melanoma skin sites and morphology in Croatian National Cancer Registry 2000-2014: an overview of recent progress

Mortality rates and five-year relative survival for malignant melanomaMM of the skin in Croatia are poor compared with most Europeancountries. Epidemiological data recorded at the National Cancer Registry(CNCR) are used for informing various decision-makers and researchers, aswell as comparisons with other countries. We analyzed CNCR data on MMskin sites and morphology for 2000-2007 and 2008-2014 and comparedthem with European 2000-2007 data. We further stratified skin site analysesin Croatia by sex, different age groups, and sources of reports. We found 52%of case with “non-specified sites” in Croatia in 2000-2007; however, that ratiodecreased to 36% in 2008-2014, with 29% of registered MM cases occurringon the trunk, 22% on the limbs, and 13% on the head and neck. The ratio of“non-specified sites” cases in reports originating from university hospitalsdecreased by 25% and by 9.2% in those from general hospitals. The ratioof “not otherwise specified” among histologically verified cases decreasedfrom 96% in 2000-2007 to 84% in 2008-2014. Our results reveal a substantialratio of inadequately reported cases, in particular when compared to data atthe European level, where in 2000-2007 only 7.7% of cases were from “nonspecifiedsites” and 19% were of non-specified morphology. Irrespective ofrecent progress, the proportion of unspecified cases still hampers insight into sitedistribution by subgroups. A further increase in the overall completeness ofMM data within CNCR is needed to enable research-informed improvementof melanoma control in the country. Our findings call for engagement ofall stakeholders in optimization of the national melanoma registration processesand using models such as RegisTree to facilitate these initiatives.</p

Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe

Background: Since the incidence of the histological subtypes of lung cancer in industrialised countries has changed dramatically over the last two decades, we reviewed trends in the incidence and prognosis in North America, Australia, New Zealand and Europe, according to period of diagnosis and birth cohort and summarized explanations for changes in mortality. Methods: Review of the literature based on a computerised search (Medline database 1966-2000). Results: Although the incidence of lung cancer has been decreasing since the 1970s/1980s among men in North America, Australia, New Zealand and north-western Europe, the age-adjusted rate continues to increase among women in these countries, and among both men and women in southern and eastern Europe. These trends followed changes in smoking behaviour. The proportion of adenocarcinoma has been increasing over time; the most likely explanation is the shift to low-tar filter cigarettes during the 1960s and 1970s. Despite improvement in both the diagnosis and treatment, the overall prognosis for patients with non-small-cell lung cancer hardly improved over time. In contrast, the introduction and improvement of chemotherapy since the 1970s gave rise to an improvement in - only short-term (<2 years) - survival for patients with small-cell lung cancer. Conclusions: The epidemic of lung cancer is not over yet, especially in southern and eastern Europe. Except for short-term survival of small cell tumours, the prognosis for patients with lung cancer has not improved significantly. Copyrigh

Rising incidence of breast cancer among female cancer survivors: implications for surveillance.

The number of female cancer survivors has been rising rapidly. We assessed the occurrence of breast cancer in these survivors over time. We computed incidence of primary breast cancer in two cohorts of female cancer survivors with a first diagnosis of cancer at ages 30+ in the periods 1975–1979 and 1990–1994. Cohorts were followed for 10 years through a population-based cancer registry. Over a period of 15 years, the incidence rate of breast cancer among female cancer survivors increased by 30% (age-standardised rate ratio (RR-adj): 1.30; 95% CI: 1.03–1.68). The increase was significant for non-breast cancer survivors (RR-adj: 1.41, 95% CI: 1.04–2.75). During the study period, the rate of second breast cancer stage II tripled (RR-adj: 3.10, 95% CI: 1.73–5.78). Non-breast cancer survivors had a significantly (P value=0.005) more unfavourable stage distribution (62% stage II and III) than breast cancer survivors (32% stage II and III). A marked rise in breast cancer incidence among female cancer survivors was observed. Research to optimise follow-up strategies for these women to detect breast cancer at an early stage is warranted

Substantial variation in therapy for colorectal cancer across Europe: EUROCARE analysis of cancer registry data for 1987

To provide a quantitative description of the treatments applied to malignant colorectal cancer across Europe, we analysed all cases (11 333) of colorectal cancer registered in 1987 by 15 Cancer Registries in eight European countries. In a third of cancer registries, therapy was known for all cases, in the others 1-15% of registrations lacked treatment information. Eighty per cent of all patients received surgical resection, ranging from 58% (Estonia) to 92% (Tarn). The proportion of resections decreased with advancing age (85-73% for colon cancer; 85-70% for rectal cancer for 74 years, respectively). Only 4% of colon cancer patients received adjuvant or palliative chemotherapy, range 1-12%. Sixteen per cent of rectal cancer patients received radiotherapy with great inter-registry variability (1-43%). Since the proportion of surgically resected patients correlated positively with the 5-year relative survival probability reported by the recently published EUROCARE study, this may be part of the explanation for the major differences in survival for these cancers among different European populations. The most likely determinant of this correlation is stage at diagnosis, but, quality of, and access to surgery, as well as access to endoscopy, may differ among countries and registry areas, and these may also contribute to inter-country survival differences. Copyrigh

Vaginal and (uncommon) cervical cancers in the Netherlands, 1989-2003

Background: The clinical and prognostic evaluation of cervical and vaginal tumors other than squamous cell and adenocarcinomas is hampered by the low incidence, and clinical and epidemiological studies on these uncommon tumors are scarce. Having close affinity with the pathology laboratories, the Netherlands Cancer Registry offers a great opportunity to study frequency, stage, treatment, and survival of uncommon tumors in the cervix and vagina and separately, the clear cell adenocarcinoma of the vagina and cervix.\ud \ud Methods: All invasive cervical tumors (n = 10,570) and all in situ and invasive vaginal tumors (n = 778) diagnosed in the Netherlands during 1989-2003 were selected from the Netherlands Cancer Registry. Age, stage at diagnosis, and treatment were described for each histological subgroup to find differences between common and uncommon tumors, including 5-year relative survival rates.\ud \ud Results: Twenty-five patients (3%) with cervical cancer subsequently developed a vaginal tumor (during 1989-2003), and 19 of these patients underwent hysterectomy for their cervical cancer. A significantly worse prognosis was found for patients with small cell neuroendocrine cervical tumors and for patients with vaginal melanomas. Patients with clear cell adenocarcinoma of the vagina and cervix were found across all age categories.\ud \ud Conclusions: The less common histological types of cervical and vaginal cancers were clearly different from squamous cell carcinomas, especially with respect to age at diagnosis and survival rates. Spreading population-based knowledge of effects of treatment of these uncommon tumors should help clinical decision making and therefore improve prognosis

Socioeconomic status and breast cancer survival in the southeastern Netherlands, 1980-1989

Socioeconomic differences in breast cancer survival in the southeastern Netherlands between 1980 and 1989 were studied (n = 3928), as was the impact of prognostic factors (stage at diagnosis, morphology, and treatment) on such differences. An area-based measure of Socioeconomic status (SES) in five groups, based on the postcode of residence at the time of diagnosis, was used. In univariate analyses the relative survival rate was used to correct for causes of death other than breast cancer. The measure of outcome in multivariate analyses was the hazard ratio. The results of both univariate and multivariate analyses suggested a small survival advantage for the higher SES groups. In a mode